Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.62 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774628 | 0.90 | ASIC3 (0.55) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL3194702 | 0.86 | CYP2A6 (0.74) | CYP2A6HSP90AA1HSP90AB1PTK2CYP3A4 | |
| SCHEMBL27969164 | 0.82 | HSP90AA1 (0.53) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL18745707 | 0.81 | CYP2A6 (0.59) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL3068958 | 0.81 | HSP90AA1 (0.56) | CYP2A6HSP90AA1HSP90AB1PTK2CYP3A4 | |
| SCHEMBL12925581 | 0.80 | CYP2A6 (0.67) | CYP2A6HSP90AA1HSP90AB1PTK2CYP3A4 | |
| SCHEMBL18905222 | 0.80 | CYP19A1 (0.69) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL13403437 | 0.80 | ASIC3 (0.61) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL12278878 | 0.80 | HPGDS (0.55) | CYP2A6ASIC3HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL10031168 | 0.78 | CYP2A6 (0.65) | CYP2A6HSP90AA1HSP90AB1PTK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185330-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-08-16 | — | — | EP | disclosed |
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| EP-3663283-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION | SAMSUNG DISPLAY CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3301097-B1 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | SAMSUNG DISPLAY CO LTD (KR) | 2020-08-19 | — | — | EP | disclosed |
| EP-3693372-A1 | BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2020-08-12 | — | — | EP | disclosed |
| CN-107406425-B | As adenosine A2bReceptor antagonists and melatonin MT32-aminopyridine derivatives of ligands for receptors | 帕罗生物制药有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-110818683-A | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-02-21 | — | — | CN | disclosed |
| EP-3339395-B1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-04-09 | — | — | US | disclosed |
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1997649-A | Inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2007-07-11 | — | — | CN | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20060173186-A1 | Transition-metal-catalyzed carbon-nitrogen and carbon-carbon bond-forming reactions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-08-03 | — | — | US | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | ADORA2B, MTNR1A, ADORA3 | CYP2A6 776/4885ASIC3 500/4885HSP90AA1 4403/4885 |
| US-20060173186-A1 | Transition-metal-catalyzed carbon-nitrogen and carbon-carbon bond-forming reactions | NBAS, APEX1, CBR3 | CYP2A6 1183/4885ASIC3 2486/4885HSP90AA1 4580/4885 |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | CYP2A6 192/4885ASIC3 3905/4885HSP90AA1 2380/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | CYP2A6 4452/4885ASIC3 3689/4885HSP90AA1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.